Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Cyclopharm Limited ( (AU:CYC) ).
Cyclopharm plans to issue up to 14.7 million new shares via a placement and a further 2.1 million through a securities purchase plan, with record, closing, and issue dates set through March 2026, signaling a sizeable capital raise to support its expansion objectives. The dual-structure offering should bolster liquidity, broaden the shareholder base, and provide funding capacity that may enhance Cyclopharm’s competitive positioning and operational execution in nuclear medicine diagnostics.
The most recent analyst rating on (AU:CYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited operates in medical diagnostics, specialising in radiopharmaceutical products such as Technegas for pulmonary imaging, targeting respiratory disease assessments across global nuclear medicine markets.
Average Trading Volume: 65,528
Technical Sentiment Signal: Hold
Current Market Cap: A$130M
Find detailed analytics on CYC stock on TipRanks’ Stock Analysis page.